Summary of response in the overall population by IRC and investigator assessments
| . | IRC assessment N = 103 . | Investigator assessment N = 103 . |
|---|---|---|
| ORR, n (%) | 88 (85.4) | 82 (79.6) |
| CR | 63 (61.2) | 60 (58.3) |
| PR | 25 (24.3) | 22 (21.4) |
| Stable disease, n (%) | 3 (2.9) | 7 (6.8) |
| Progressive disease, n (%) | 8 (7.8) | 9 (8.7) |
| Not evaluable, n (%) | 4 (3.9) | 5 (4.9) |
| Time to response, median (range), mo | 1.5 (0.9-3.0) | 1.5 (0.9-11.1) |
| Time to CR, median (range), mo | 2.6 (1.3-22.1) | 1.7 (1.3-10.7) |
| . | IRC assessment N = 103 . | Investigator assessment N = 103 . |
|---|---|---|
| ORR, n (%) | 88 (85.4) | 82 (79.6) |
| CR | 63 (61.2) | 60 (58.3) |
| PR | 25 (24.3) | 22 (21.4) |
| Stable disease, n (%) | 3 (2.9) | 7 (6.8) |
| Progressive disease, n (%) | 8 (7.8) | 9 (8.7) |
| Not evaluable, n (%) | 4 (3.9) | 5 (4.9) |
| Time to response, median (range), mo | 1.5 (0.9-3.0) | 1.5 (0.9-11.1) |
| Time to CR, median (range), mo | 2.6 (1.3-22.1) | 1.7 (1.3-10.7) |